7-mono-O-(β-hydroxyetyl)rutoside | 23869-24-1

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 黄酮类化合物
• 英文名称: 7-mono-O-(β-hydroxyetyl)rutoside
• 英文别名: 7-mono-hydroxyethyl rutoside；7-monohydroxyethylrutoside；monohydroxyethylrutoside；monoxerutin；monoHER；2-(3,4-dihydroxyphenyl)-5-hydroxy-7-(2-hydroxyethoxy)-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxychromen-4-one
• CAS: 23869-24-1
• 化学式: C₂₉H₃₄O₁₇
• 分子量: 654.579
• InChiKey: MBHXKZDTQCSVPM-BDAFLREQSA-N

物化性质

• 熔点：
  159 - 165°C
• 溶解度：
  DMSO（微溶、超声处理）、甲醇（微溶、加热、超声处理）

计算性质

• 辛醇/水分配系数(LogP)：
  -1.6
• 重原子数：
  46
• 可旋转键数：
  9
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  275
• 氢给体数：
  10
• 氢受体数：
  17

反应信息

• 作为反应物：
  描述：

  7-mono-O-(β-hydroxyetyl)rutoside 以57的产率得到Trihydroxyethylrutin
  参考文献：
  名称：

  PREPARATION METHOD OF TRIHYDROXYETHYL RUTOSIDE

  摘要：

  本发明涉及一种三羟乙基芦丁的制备方法。该方法首先将芦丁制备成纯度大于或等于98%的7-单羟乙基芦丁，然后将7-单羟乙基芦丁进行羟乙基化反应，得到含有少于2%非羟乙基化芦丁衍生物的曲克芦丁。曲克芦丁中7,3'-4'-三羟乙基芦丁的含量大于80%。进一步对产物进行纯化，以获得纯度大于或等于98%的7,3'-4'-三羟乙基芦丁。

  公开号：

  US20160096860A1
• 作为产物：
  描述：

  芦丁 以95的产率得到7-mono-O-(β-hydroxyetyl)rutoside
  参考文献：
  名称：

  PREPARATION METHOD OF TRIHYDROXYETHYL RUTOSIDE

  摘要：

  本发明涉及一种三羟乙基芦丁的制备方法。该方法首先将芦丁制备成纯度大于或等于98%的7-单羟乙基芦丁，然后将7-单羟乙基芦丁进行羟乙基化反应，得到含有少于2%非羟乙基化芦丁衍生物的曲克芦丁。曲克芦丁中7,3'-4'-三羟乙基芦丁的含量大于80%。进一步对产物进行纯化，以获得纯度大于或等于98%的7,3'-4'-三羟乙基芦丁。

  公开号：

  US20160096860A1

文献信息

• [EN] PYRAZOLO [4, 3-D] PYRIMIDINES USEFUL AS KINASE INHIBITORS<br/>[FR] PYRAZOLO[4,3-D]PYRIMIDINES UTILES EN TANT QU'INHIBITEURS DE KINASES
  申请人：ORIGENIS GMBH

  公开号：WO2012143144A1

  公开（公告）日：2012-10-26

  The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.

  本发明涉及一种能够抑制一个或多个激酶，特别是SYK（脾酪氨酸激酶）、LRRK2（富含亮氨酸重复的激酶2）和/或MYLK（肌球蛋白轻链激酶）或其突变体的化合物的新颖化合物（I）的公式。这些化合物在治疗各种疾病中发挥作用。这些疾病包括自身免疫疾病、炎症性疾病、骨疾病、代谢性疾病、神经和神经退行性疾病、癌症、心血管疾病、过敏、哮喘、阿尔茨海默病、帕金森病、皮肤疾病、眼部疾病、传染病和与激素相关的疾病。
• [EN] HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES EN TANT QU'INHIBITEURS DE KINASES
  申请人：ORIGENIS GMBH

  公开号：WO2012143143A1

  公开（公告）日：2012-10-26

  The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.

  本发明涉及一种能够抑制一个或多个激酶，特别是SYK（脾酪氨酸激酶）、LRRK2（富含亮氨酸重复激酶2）和/或MYLK（肌球蛋白轻链激酶）或其突变体的化合物的新颖化合物（I）的公式。这些化合物在治疗各种疾病中发挥作用。这些疾病包括自身免疫疾病、炎症性疾病、骨疾病、代谢性疾病、神经和神经退行性疾病、癌症、心血管疾病、过敏、哮喘、阿尔茨海默病、帕金森病、皮肤疾病、眼部疾病、传染病和与激素相关的疾病。
• Low-emulsifier or emulsifier-free systems of the oil-in-water type with a content of stabilizers and an amino-substituted hydroxybenzophenone
  申请人：——

  公开号：US20030124158A1

  公开（公告）日：2003-07-03

  Cosmetic or dermatological preparations which represent finely disperse systems of the oil-in-water type, comprising a) an oil phase, b) a water phase, c) one or more stabilizers, d) at most 2.00% by weight of one or more emulsifiers, and e) an amino-substituted hydroxybenzophenone of the formula I 1

  化妆品或皮肤科制剂，代表油包水型的细分散系统，包括 a) 油相， b) 水相， c) 一种或多种稳定剂， d) 最多占总重量的2.00%的一种或多种乳化剂，以及 e) 公式I的氨基取代羟基苯酮 1
• Preparation having antioxidant properties
  申请人：Merck Patent GmbH

  公开号：US20040067894A1

  公开（公告）日：2004-04-08

  The invention relates to a preparation having antioxidant properties, comprising at least one compound of the formula I 1 where R 1 to R 10 may be identical or different and are selected from H, OR 11 , straight-chain or branched C 1 - to C 20 -alkyl groups, straight-chain or branched C 3 - to C 20 -alkenyl groups, straight-chain or branched C 1 - to C 20 -hydroxyalkyl groups, where the hydroxyl group may be bonded to a primary or secondary carbon atom of the chain and furthermore the alkyl chain may also be interrupted by oxygen, and/or C 3 - to C 10 -cycloalkyl groups and/or C 3 - to C 12 -cycloalkenyl groups, where the rings may each also be bridged by —(CH 2 ) n — groups, where n=1 to 3, where all OR 11 are, independently of one another, OH, C 1 - to C 20 -alkoxy groups, C 3 - to C 20 -alkenyloxy groups, straight-chain or branched C 1 - to C 20 -hydroxyalkoxy groups and/or C 3 - to C 10 -cycloalkoxy groups and/or C 3 - to C 12 -cycloalkenyloxy groups, where the rings may each also be bridged by —(CH 2 ) n — groups, where n=1 to 3, and/or mono- and/or oligoglycosyl radicals, with the proviso that at least 3 radicals from R 1 to R 7 are OH and that at least 2 pairs of adjacent —OH groups are present in the molecule, or R 2 , R 5 and R 6 are OH and the radicals R 1 , R 3 , R 4 and R 7-10 are H.

  该发明涉及一种具有抗氧化性能的制剂，包括至少一种具有以下式I1的化合物，其中R1到R10可能相同也可能不同，选择自H、OR11、直链或支链的C1到C20烷基基团、直链或支链的C3到C20烯基基团、直链或支链的C1到C20羟基烷基基团，其中羟基可能连接到链的一级或二级碳原子上，此外，烷基链也可能被氧原子中断，和/或C3到C10环烷基基团和/或C3到C12环烯基基团，其中环可能也通过—(CH2)n—基团相互连接，其中n=1到3，其中所有的OR11都是独立的，OH、C1到C20烷氧基团、C3到C20烯氧基团、直链或支链的C1到C20羟基烷氧基团和/或C3到C10环烷氧基团和/或C3到C12环烯氧基团，其中环可能也通过—(CH2)n—基团相互连接，其中n=1到3，和/或单糖和/或寡糖基团，但至少3个从R1到R7的基团是OH，并且分子中至少有2对相邻的—OH基团，或者R2、R5和R6是OH，基团R1、R3、R4和R7-10是H。
• 트리하이드록시에틸 루토사이드의 제조방법
  申请人：JINAN XINLITE TECHNOLOGY CO., LTD 지난 신라이트 테크놀로지 컴퍼니 리미티드(520150722386)

  公开号：KR20160029012A

  公开（公告）日：2016-03-14

  본 발명은 트리하이드록시에틸 루토사이드(trihydroxyethyl rutoside)의 제조방법에 관한 것으로서, 상기 방법은 먼저 루틴(rutin)을 중량 함량 98% 이상의 7-모노하이드록시에틸 루토사이드(7-monohydroxyethyl rutoside)로 제조한 후, 계속하여 7-모노하이드록시에틸 루토사이드에 대하여 하이드록시에틸화(hydroxyethylated)를 진행하여 비(非)하이드록시에틸화 루토사이드 유도체 불순물이 2%보다 작은 트록세루틴(troxerutin)을 얻고, 상기 트록세루틴 중 7,3',4'-트리하이드록시에틸 루토사이드 중량 함량은 80%보다 크고, 상기 산물을 계속 정제하여 중량 함량이 98% 이상인 7,3',4'-트리하이드록시에틸 루토사이드를 얻을 수 있다.

  这项发明涉及三羟乙基芦荟苷(trihydroxyethyl rutoside)的制备方法，该方法首先制备重量含量为98％以上的7-单羟乙基芦荟苷(7-monohydroxyethyl rutoside)，然后继续对7-单羟乙基芦荟苷进行羟乙基化(hydroxyethylated)，以获得非羟乙基化芦荟苷衍生物杂质小于2％的曲塞鲁汀(troxerutin)。其中，重量含量为7,3',4'-三羟乙基芦荟苷的重量含量大于80％，然后持续精制该产物，即可获得重量含量为98％以上的7,3',4'-三羟乙基芦荟苷。